92 low- and middle-income economies eligible to get access to COVID-19 vaccines through Gavi COVAX Advance Market Commitment (AMC).

A new landmark collaboration between Serum Institute of India (SII). the world’s largest vaccine manufacturer by volume, Gavi and the Bill & Melinda Gates Foundation will accelerate the manufacture and delivery of up to 100 million doses of COVID-19 vaccines for low- and middle-income countries (LMICs) including Bangladesh as part of the Gavi COVAX AMC, a mechanism within the COVID-19 Vaccine Global Access (COVAX) Facility as early as the first half of 2021.

COVAX: Ensuring global equitable access to COVID-19 vaccines

The Gavi Board agreed upon the final list of 92 countries that will be supported by the AMC. Under the new collaboration, AstraZeneca’s candidate vaccine, if successful, will be available to 57 Gavi-eligible countries. Novavax’s candidate, if successful, will be available to all 92 countries supported by the AMC. These countries align with SII’s licensing agreements with the two partners.

The deal is additional to a Memorandum of Understanding between AstraZeneca and Gavi, announced in June, which will guarantee an additional 300 million doses of AstraZeneca’s candidate vaccine to the wider COVAX Facility, to be supplied upon licensure or prequalification. These two deals can help guarantee access to early doses for the most vulnerable on a truly global scale.